Grants Awarded

EpicentRx has been awarded five prestigious and rigorously peer-reviewed grants that provide not only much-needed funding but also critical third-party validation. These grants, totaling over five million USD, support the acceleration of development and commercialization of our lead small molecule NRP3 inhibitor, RRx-001 (nibrozetone), both as a neuroprotective/anti-neurotoxic agent and as a treatment for endometriosis.

MJFF Therapeutic Pipeline Potential Program to evaluate the therapeutic potential of RRx-001 in Parkinson’s Disease

Fight MND for the treatment of amyotrophic lateral sclerosis/motor neuron disease (ALS/MND) with RRx-001
DoD CNS Toxic Exposures Program for the study of RRx-001 as a medical countermeasure against military-related toxic exposures
Department of Defense (DoD) Congressionally Directed Medical Research Program (CDMRP) for the study of RRx-001 in Parkinson’s Disease
Endometriosis to be announced
SUSAN KNOX, M.D.
Associate Professor of Radiation Oncology, Emerita, Stanford University

Stanford Hospital and Clinics, Lucile Packard Children’s Hospital

THEODORE LAWRENCE, M.D., Ph.D.
Chair of the Department of Radiation Oncology, University of Michigan

Isadore Lampe Professor of Radiation Oncology

KENNETH C. ANDERSON, M.D.
Kraft Family Professor of Medicine, Medicine, Harvard Medical School

Physician, Oncology, Brigham And Women’s Hospital

SUSAN KNOX, M.D.
Associate Professor of Radiation Oncology, Emerita, Stanford University

Stanford Hospital and Clinics, Lucile Packard Children’s Hospital

THEODORE LAWRENCE, M.D., Ph.D.
Chair of the Department of Radiation Oncology, University of Michigan

Isadore Lampe Professor of Radiation Oncology

KENNETH C. ANDERSON, M.D.
Kraft Family Professor of Medicine, Medicine, Harvard Medical School

Physician, Oncology, Brigham And Women’s Hospital